Robert E. Wanerman, a Member of the Firm in the Health Care and Life Sciences practice, in the firm’s Washington, DC, office, was quoted in Modern Healthcare, in “CMS Can Order Trials Before OKing Payment for New Tech,” by Virgil Dickson.
Following is an excerpt:
This will likely mean the use of blinding or placebos, argued Robert Wanerman, an attorney at Epstein Becker & Green who specializes in coverage, coding and reimbursement for medical technologies under Medicare. If patients are desperate for care, they may balk at the idea of participating in a study where they may get a placebo. “You may not be able to get anyone in the trial,” Wanerman said. “Or people will likely drop out and get care elsewhere.”
